cariprazine
Sign in to saveCariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia and bipolar disorder. It is also prescribed as an add-on treatment for bipolar depression and major depressive disorder. Cariprazine acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. It is a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors. It is taken by mouth. The most prevalent side effects include nausea, mild sedation, fatig
Key facts
- Drug.image
- Cariprazine.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.image2
- Cariprazine ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 250
- Drug.tradename
- Vraylar, Reagila, Symvenu
- Drug.DailyMedID
- Cariprazine
- Drug.licence_US
- Cariprazine
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.class
- Atypical antipsychotic
- Drug.ATC_prefix
- N05
- Drug.ATC_suffix
- AX15
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Research
621 papers- Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy.Cureus · 2023
- Cariprazine.2012
- Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential.Medical science monitor : international medical journal of experimental and clinical research · 2024
- Cariprazine.2006
- Cariprazine (Vraylar®).1994
via PubMed
Article
7 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Research
- References
Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia and bipolar disorder. It is also prescribed as an add-on treatment for bipolar depression and major depressive disorder. Cariprazine acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. It is a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors. It is taken by mouth. The most prevalent side effects include nausea, mild sedation, fatigue, diabetes regardless of weight changes, and dizziness. At higher dosages, there is an increased risk for restlessness, insomnia, and tremors.
thumb|Bottles of 3mg and 4.5mg Vraylar (cariprazine) capsules showing 3mg capsules below
Gallery (2)
Connections
Categories
2,3-DichlorophenylpiperazinesAtypical antipsychoticsChemicals using indexlabelsDimethylamino compoundsDopamine antagonistsDrugs developed by AbbVieDrugs with non-standard legal statusH1 receptor antagonistsMood stabilizersMultiple chemicals in Infobox drugSerotonin-dopamine activity modulatorsSerotonin receptor antagonists